BIDU-SW
09888
JD HEALTH
06618
ALI HEALTH
00241
NTES-S
09999
JD-SW
09618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|
Turnover | 59.04%365.99M | 57.97%527.75M | 50.67%230.13M | 87.78%334.09M | 113.67%152.74M | 543.89%177.91M | --71.48M | 461.95%27.63M | --4.92M |
Operating income | 59.04%365.99M | 57.97%527.75M | 50.67%230.13M | 87.78%334.09M | 113.67%152.74M | 543.89%177.91M | 71.48M | 461.95%27.63M | 4.92M |
Cost of sales | -76.64%-105.08M | -75.34%-142.77M | -59.62%-59.49M | -76.88%-81.42M | -92.49%-37.27M | -305.77%-46.03M | ---19.36M | -204.54%-11.34M | ---3.73M |
Operating expenses | -76.64%-105.08M | -75.34%-142.77M | -59.62%-59.49M | -76.88%-81.42M | -92.49%-37.27M | -305.77%-46.03M | -19.36M | -204.54%-11.34M | -3.73M |
Gross profit | 52.90%260.91M | 52.37%384.99M | 47.77%170.65M | 91.59%252.67M | 121.54%115.48M | 709.73%131.88M | 52.12M | 1,266.36%16.29M | 1.19M |
Selling expenses | -6.73%-79.98M | -16.90%-163.83M | -40.52%-74.94M | -47.10%-140.14M | -107.13%-53.33M | -365.79%-95.27M | ---25.75M | -202.60%-20.45M | ---6.76M |
Administrative expenses | 13.44%-43.59M | -4.35%-114.09M | -2.18%-50.36M | -8.69%-109.34M | 9.01%-49.28M | -224.60%-100.6M | ---54.16M | -82.71%-30.99M | ---16.96M |
Research and development expenses | 22.37%-101.54M | -11.80%-261.01M | -39.10%-130.81M | -38.88%-233.46M | -92.00%-94.04M | -133.26%-168.1M | ---48.98M | -35.90%-72.07M | ---53.03M |
Impairment and provision | -166.67%-16K | 37.50%-15K | -160.00%-6K | -14.29%-24K | --10K | ---21K | ---- | ---- | ---- |
-Other impairment is provision | -166.67%-16K | 37.50%-15K | -160.00%-6K | -14.29%-24K | --10K | ---21K | ---- | ---- | ---- |
Special items of operating profit | -92.79%817K | -111.73%-2.57M | -42.75%11.33M | 11.51%21.89M | 307.89%19.79M | 178.03%19.63M | --4.85M | -28.36%7.06M | --9.86M |
Operating profit | 149.37%36.6M | 24.89%-156.52M | -20.78%-74.13M | 1.92%-208.4M | 14.65%-61.38M | -112.13%-212.48M | -71.91M | -52.45%-100.16M | -65.7M |
Financing income | -11.91%34.58M | -17.29%79.04M | 8.13%39.26M | 629.84%95.57M | 1,485.33%36.3M | 3,537.22%13.09M | --2.29M | 304.49%360K | --89K |
Financing cost | -251.16%-1.22M | -73.27%-1.25M | 19.91%-346K | -135.18%-722K | -364.52%-432K | 53.90%-307K | ---93K | 35.65%-666K | ---1.04M |
Share of profits of associates | ---1.1M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Earning before tax | 295.51%68.87M | 30.66%-78.73M | -38.11%-35.22M | 43.13%-113.56M | 63.42%-25.5M | -98.76%-199.69M | -69.72M | -50.75%-100.47M | -66.65M |
Tax | ---- | ---- | ---291K | ---- | ---- | ---- | ---- | ---- | ---- |
After-tax profit from continuing operations | 293.91%68.87M | 30.66%-78.73M | -39.25%-35.51M | 43.13%-113.56M | 63.42%-25.5M | -98.76%-199.69M | -69.72M | -50.75%-100.47M | -66.65M |
Earning after tax | 293.91%68.87M | 30.66%-78.73M | -39.25%-35.51M | 43.13%-113.56M | 63.42%-25.5M | -98.76%-199.69M | -69.72M | -50.75%-100.47M | -66.65M |
Profit attributable to shareholders | 293.91%68.87M | 30.66%-78.73M | -39.25%-35.51M | 43.13%-113.56M | 63.42%-25.5M | -98.76%-199.69M | -69.72M | -50.75%-100.47M | -66.65M |
Basic earnings per share | 297.31%0.2125 | 29.41%-0.24 | -34.63%-0.1077 | 50.00%-0.34 | 70.37%-0.08 | -30.77%-0.68 | -0.27 | -36.84%-0.52 | -0.38 |
Diluted earnings per share | 295.17%0.2102 | 29.41%-0.24 | -34.63%-0.1077 | 50.00%-0.34 | 70.37%-0.08 | -30.77%-0.68 | -0.27 | -36.84%-0.52 | -0.38 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.